Great breakdown, Leandro. The shift in the growth algorithm from volume to price is the most concerning part for The IGP Paradox. If 2026 is indeed an “air pocket” before the 2027/28 innovation cycle, do you think management is using the ERP/accounting transition specifically to smooth over what would otherwise be a stagnant year?
It feels like they are buying time for the pipeline to catch up.
I don't think the EP/accounting change is a very meaningful tailwind to the guide, but timing feels a bit off! I also somewhat believe that if you had to made that change you'd make it through a transition year, though
I thought you might be interested in this. I went to the vet yesterday with my dog - it's Vets for Pets in the UK (one of the largest chains). It's a labrador with itchy skin which we treat regularly with either Cytopoint (injectable) or Apoquel.
However, for the first time, the vet heavily pushed us towards Zenrelia. She said it's a new treatment not long on the market. The rationale she gave for why it is recommended ahead of Apoquel is fewer long term side effects/concerns. I don't know whether that is right but that's what she said.
So long story short our dog is on Zenrelia now (an Elanco brand) because of course we followed the vet's recommendation. It does make me think that competition is significantly ramping up for Zoetis in dermatology. But I don't know the company well.
Great breakdown, Leandro. The shift in the growth algorithm from volume to price is the most concerning part for The IGP Paradox. If 2026 is indeed an “air pocket” before the 2027/28 innovation cycle, do you think management is using the ERP/accounting transition specifically to smooth over what would otherwise be a stagnant year?
It feels like they are buying time for the pipeline to catch up.
I don't think the EP/accounting change is a very meaningful tailwind to the guide, but timing feels a bit off! I also somewhat believe that if you had to made that change you'd make it through a transition year, though
Love your work Best Anchor Stocks.
I thought you might be interested in this. I went to the vet yesterday with my dog - it's Vets for Pets in the UK (one of the largest chains). It's a labrador with itchy skin which we treat regularly with either Cytopoint (injectable) or Apoquel.
However, for the first time, the vet heavily pushed us towards Zenrelia. She said it's a new treatment not long on the market. The rationale she gave for why it is recommended ahead of Apoquel is fewer long term side effects/concerns. I don't know whether that is right but that's what she said.
So long story short our dog is on Zenrelia now (an Elanco brand) because of course we followed the vet's recommendation. It does make me think that competition is significantly ramping up for Zoetis in dermatology. But I don't know the company well.
Cheers,
Charlie